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Background: Testing for human epidermal growth factor receptor-2 (HER-2) in breast cancer is performed by either
immunohistochemistry (IHC) or in situ hybridization (ISH). The growth factor receptor-bound protein-7 (GRB7) gene
is in close proximity to HER-2 on chromosome 17q11-12 and codes a signal transduction molecule shown to be an
independent adverse marker in breast cancer.
Methods: HER-2 and GRB7 protein expression from 613 frozen breast tumors was determined by Western analysis.
HER-2 protein results were confirmed with IHC. Commercial HER-2 FISH was performed on a subset of tumors with
multi-probe FISH used to assess the extent of HER-2 gene amplification. mRNA expression was determined by
Multi-plex RT-PCR.
Results: Seven tumors with GRB7 protein over-expression scored HER-2 FISH amplified but had no HER-2 protein
over-expression. Four of the 7 tumors showed elevated GRB7 but not HER-2 mRNA over-expression. The breast
cancer cell line HCC3153 did not over-express HER-2 protein but showed HER-2 FISH amplification of a limited
segment around the HER-2 gene. Ten breast cancer tumors from the TCGA database had gene copy number
increases around HER-2 without HER-2 mRNA or protein over-expression.
Conclusions: A subset of human breast cancers that test positive with FISH for HER-2 gene amplification do not
over-express HER-2 protein. One mechanism for this discordance is the incomplete amplification of the smallest HER-2
region of chromosome 17q11-12, which includes GRB7. HER-2 gene amplification without protein over-expression is
clinically significant because patients with such tumors are unlikely to benefit from HER-2 targeted therapy.Introduction
Amplification of chromosome 17q11-12 occurs in about
20-25% of breast tumors leading to over-expression of
the human epidermal growth factor receptor 2 gene
(HER-2 or ERBB2) (Slamon et al. 1987; Slamon et al.
1989; Ross et al. 2003). The HER-2 gene encodes a tyro-
sine kinase receptor and is the best-studied gene present
in the amplicon. Because chromosome 17q11-12 ampli-
fication was initially detected in frozen breast tumor
specimens by Southern blot analysis using a HER-2
probe, it is historically known as HER-2 amplification* Correspondence: luohs@ohsu.edu
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in any medium, provided the original work is p17q11-12 amplification has been subsequently found to
correlate with HER-2 over-expression on both the mRNA
and protein levels in a molecularly fully characterized
breast tumor cohort (Press et al. 2002). Most studies of
chromosome 17q11-12 amplification have focused on the
HER-2 gene such that HER-2 gene amplification and
HER-2 protein over-expression have come to be recog-
nized as important markers of clinically aggressive breast
cancer and the target of specifically directed therapies
(Press et al. 2008; Goldenberg 1999; Xia et al. 2002).
HER-2 protein, when over-expressed, is the molecular
target for specific therapies such as Trastuzumab, a human-
ized monoclonal antibody that binds to the extracellular
domain of the HER-2 protein (Goldenberg 1999), and
Lapatinib a small molecule inhibitor of the intracellular
tyrosine kinase domain of both HER-2 and epidermal
growth factor receptor (HER-1) (Xia et al. 2002; Kim &Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Luoh et al. SpringerPlus 2013, 2:386 Page 2 of 10
http://www.springerplus.com/content/2/1/386over-expression is required for the responsiveness to either
therapy (Press et al. 2008; Mass et al. 2005; Di Leo et al.
2008). Both Trastuzumab and Lapatinib have received
approval by the FDA for the treatment of HER-2 positive
breast cancer and are associated with improved clin-
ical outcome in metastatic (Slamon et al. 2001;
Geyer et al. 2006) and, for Trastuzumab, early stage
HER-2 positive breast cancer (Romond et al. 2005;
Piccart-Gebhart et al. 2005).
Despite success in treating HER-2 positive breast
cancer patients with these therapies, considerable debate
continues to exist regarding which method of testing of
HER-2 represents the best assessment of a patient’s
HER-2 status (Bartlett et al. 2001; Wolff et al. 2007;
Sauter et al. 2009; Press et al. 2005; Hammock et al. 2003;
Troxell et al. 2006; Tse et al. 2011; Pauletti et al. 1996;
Pauletti et al. 2000; Perez et al. 2012). The FDA has
approved immunohistochemical (IHC) assay methods
(Herceptest and Pathway), fluorescence in situ hybridization
(FISH) assays (PathVysion; INFORM; and FISH pharmDx)
and the newer chromogenic in situ hybridization (CISH)
assays (SPOT-Light; INFORM dual CISH; and CISH
pharmDx). The American Society of Clinical Oncology
(ASCO) and the College of American Pathologists (CAP)
recently created a set of joint guidelines for the laboratory
evaluation of HER-2 status (Wolff et al. 2007). They
recommend either using IHC assays for initial evaluation
of HER-2 status followed by reflex testing by FISH for
some IHC categories (i.e. 2+) or utilization of FISH
in initial testing (Wolff et al. 2007).
In addition to HER-2, there are a number of other
chromosome 17q11-12 genes, including closely neighboring
GRB7, which may be amplified and over-expressed
concurrently with HER-2 (Luoh 2002; Kao & Pollack 2006;
Kauraniemi & Kallioniemi 2006; Bai & Luoh 2008;
Stein et al. 1994; Glynn et al. 2010). The GRB7 gene
codes for a multi-domain signal transduction molecule,
and is known to play important roles in tumor growth
and migration (Shen & Guan 2004). The GRB7 protein
can interact with HER-2 and multiple other signaling
proteins, including receptor and non-receptor tyrosine
kinases (Shen & Guan 2004). Located less than 15 kb
away from the HER-2 gene, the GRB7 gene is contained
well within the smallest amplified region of the
HER-2 amplicon on chromosome 17q11-12. Amplification
of GRB7 and other neighboring genes is typically associated
with increased transcriptional activation and may have
significant prognostic and predictive value in breast
cancer treatment independent of the HER-2 gene
(Ramsey et al. 2011; Nadler et al. 2010).
Though they are usually over-expressed together, our
Western blotting analysis of 563 breast tumors from a
well-annotated breast tumor repository found a significant
discordance in GRB7 and HER-2 protein over-expression,allowing us to investigate the independent prognostic sig-
nificance of GRB7 protein over-expression in breast can-
cer (Ramsey et al. 2011). We found that patients whose
tumors had isolated GRB7 protein over-expression had
the worst prognosis. In addition, our studies revealed
that protein over-expression of GRB7 is a stronger
independent adverse prognostic factor than HER-2
over-expression (Ramsey et al. 2011), a conclusion
which is seemingly at odds with the widely held perspec-
tive of the role of HER-2 protein over-expression as the
sole driver of adverse prognosis in chromosome 17q11-12
amplified breast tumors. The role of GRB7 protein in
breast cancer was recently further validated when GRB7
was found to be the only significant adverse prognostic
factor from among 394 gene candidates examined in a
uniformly treated patient population with triple negative
breast cancer, an especially aggressive form of the disease
(Sparano et al. 2011; Giricz et al. 2011).
With the current study we seek to elucidate possible
mechanisms of isolated GRB7 over-expression and to
explore resultant implications for current HER-2 testing
and treatment regimens.
Methods
Tissues, cell culture, and databases
Tumor specimens analyzed in this study were derived from
the Oregon Health and Science University (OHSU) Knight
Cancer Institute Breast Cancer Repository (Ramsey et al.
2011; Christianson et al. 1998; Saez et al. 2006). These
tumors were originally submitted by community hospitals
in Oregon, Washington and Alaska to the College of
American Pathologists (CAP) - certified OHSU Hormone
Receptor Laboratory between 1985-1998, for the purpose
of routine evaluation of estrogen and progesterone
receptor proteins. Tumors were snap-frozen within thirty
minutes of biopsy or mastectomy. Frozen tissues remaining
following the completion of the analysis were banked
and have been maintained continuously frozen at –80 C.
A waiver of informed consent and HIPAA authorization
for research use of remaining tissue was approved by
Institutional Review Boards (IRB) at the Oregon
Health and Science University and community hospitals
in accordance with federal and local privacy laws
(OHSU IRB # IRB00000211).
Snap-frozen primary breast tumor tissues were also pur-
chased from the National Disease Research Interchange
(NDRI). Tumor pathology was verified and anonymized at
the sites of origin and obtained according to protocols
approved by local Institutional Review Boards.
Human breast cancer cell lines including HCC 3153 were
obtained from ATCC and the laboratory of Dr. Joe Gray
(OHSU Knight Cancer Institute) and maintained in RPMI
with 10% FCS (Neve et al. 2006). Protein extraction and
Western blotting analysis for HER-2 and GRB7 protein
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(Ramsey et al. 2011).
The Cancer Genome Atlas (TCGA) project includes a
database of comprehensive genomic and epigenetic
information currently for 847 primary breast tumors.
Data are deposited in standard formats in the TCGA Data
Coordinating Center and are available on line through a
data portal (Cancer Genome Atlas 2012).
HER-2 fluorescence in situ hybridization (FISH) analysis
HER-2 FISH was performed using the FDA-approved
Abbott PathVysion kit on 4 μm frozen sections. Our proto-
col was adjusted from the FDA recommended protocol to
fit within the confines of our study. This kit contains a
probe for the HER-2 locus (17q12, SpectrumOrange)
and the chromosome 17 centromere (CEP17) as the
chromosome 17 control probe (D17Z1,17p11.1-q11.1,
SpectrumGreen). OCT compound was removed by
three 8-12 hour washes in 4°C 70% EtOH. Following
removal of OCT compound, slides were fixed in 3:1
methanol:acetic acid for 5 minutes and baked at 95°C for
5 minutes. The preparations were then pepsin treated,
denatured, hybridized, washed, and counterstained
according to the manufacturer’s instructions. Fluorescence
was visualized on a CytoVysion image capture system
(Applied Imaging, San Jose, CA) with Nikon E800 (Nikon,
Melville, NY) microscope. HER-2 and CEP17 signals were
enumerated in 25 to 60 cells and a total HER-2/CEP17
ratio was calculated. HER-2 signal counts greater than
10 were considered too numerous to count and scored
as >10, as defined by clinical laboratory standards. A
ratio of >2.2 was considered to be amplified, <1.8,
not amplified, and 1.8 to 2.2, equivocal, based on
ASCO/CAP guidelines.
Multiple probe FISH
We developed a multi-probe FISH analysis to examine
the extent of HER-2 gene amplification using two
flanking probes that define the centromeric and telemetric
ends of the smallest amplified region of the HER-2 region;
BAC probe 3014 and 3079 respectively. Clones were
purchased from Invitrogen as GeneHogs (HS996) cultures
in glycerol stocks and grown in LB broth with chloram-
phenicol. BACs were prepared using a Qiagen Midi kit
according to protocol. Sequencing was done to confirm
clone using primers T7 and Sp6. Purified BAC DNA
from 3014 and 3079 were labeled with an Abbott
Nick Translation kit. Purified 5′ probe #3014 was
hybridized and labeled with Abbott SpectrumGreen
(green fluorescence). Purified 3′probe #3079 was labeled
with Abbott SpectrumOrange (orange fluorescence), and
the commercially available chromosome 17 centromere
probe with Abbott SpectrumAqua (aqua fluorescence).
Coalescence of red and green fluorescence signals yieldyellow signals indicating that sequences represented
by both probes are amplified in one contiguous unit.
FISH scores represent the ratio of BAC 3014 and
BAC 3079 probes to the chromosome 17 centromeric
region (D17Z1).
BAC Probe #3014 begins 35 kb upstream of the HER-2
gene promoter and extends further upstream encompassing
the centromeric end of the smallest region of amplification
(Staaf et al. 2010). The sequence of one end of the BAC
insert has been previously reported (aq154496). We
sequenced both ends of its insert and verified that
BAC #3014 does reside upstream of HER-2 and that
the insert spans 72 kb.
BAC probe #3079 begins in the middle of GRB7 gene
and extends further downstream and away from the
HER-2 gene towards the telomere. Both ends of the
BAC insert have been sequenced and verified as reported
(AQ121537 and AQ 121760). BAC #3079 maps immedi-
ately downstream and 15 kb away from the 3′-end of
the HER-2 transcription unit. #3079 represents the
telemetric end of the smallest region of amplification. The
size of insert of #3079 is 136 kb.
HER-2 immunohistochemistry (IHC)
HER-2 IHC was performed by the College of American
Pathologist (CAP) certified OHSU Clinical Immunohisto-
chemistry Laboratory using an FDA approved kit with
modifications for frozen tissues. Four mm frozen sections
were acetone fixed, and stained on an FDA-approved
Ventana XT instrument using anti-HER-2/neu 4B5 Rabbit
Monoclonal Antibody (PathwayTM, Ventana, Tucson AZ)
and a protocol optimized for frozen tissue. As slides were
not formalin fixed, antigen retrieval was not necessary.
Prediluted primary antibody was applied for 16 min at 37
degrees. Washing, secondary antibody incubation, and
detection were performed using standard instrument
protocols with Ultraview detection (Ventana).
Multi-plex RT-PCR assay
RNA was isolated from frozen tumor slices using an
Ambion RNAqueous kit. The ProtoScript MuLV Taq
RTPCR kit was used for the detection of GRB7 and HER-2
mRNAs from a single first strand cDNA synthesis followed
by PCR amplification with HER-2 or GRB7 specific primers
and β-actin as internal control (Invitrogen), respectively.
The primer concentrations for amplification of GRB7 was
2 μM, HER-2; 1 μM and β-actin; 3 μM. Thermal cycling
was initiated at 94°C for 5 minutes, followed by 34 cycles of
denaturation at 94°C for 30 seconds, annealing at 60°C for
30 seconds, and extension at 72°C for 2 minutes. Final
extension was 70°C for 5 minutes. Detection was by agarose
gel visualization. The sequence and product length of the
oligonucleotide primer pairs used in this study are as
follows: β-actin, forward primer 5′- AAG AGA GGC ATC
002 score 0






Figure 1 GRB7 and HER-2 expression in frozen breast tumor tissues. a GRB7 and HER-2 Western Blot Analysis. Densitometric analysis is
presented in Additional file 1: Table S1. b HER-2 IHC testing of HER-2 FISH positive tumors which do not over-express HER-2 protein by Western blot
analysis. Sample 012 is positive control with 3+ HER-2 over-expression; sample 002 is negative control with 0 HER-2 expression. Magnification bars
represent 50 micron. c GRB7 and HER2 mRNA expression by multiplex RT-PCR. Top panel: GRB7 and β-actin, Bottom panel: HER-2 and β-actin.
Amplified: positive control with HER-2 and GRB 7 over-expression. Non-amplified: negative control - without either HER-2 or GRB7 over-expression.
H₂O: negative control without RT product. X: 4 tumors over-expressing GRB7 but not HER-2. O: 1 tumor over-expressing both GRB7 and HER-2.
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GGG GTG TTG AA - 3′, product length 218 bp. GRB7
(growth factor receptor-bound protein 7) forward primer
5′ - AGG AAA CTT CGA GAG GAG GA- 3′, reverse
primer 5′ - TTG GAC TCG TTC ACA TCT GC -3′,
product size 847 bp. HER-2 (human epidermal growth
factor receptor 2) forward primer 5′ - GGA AAC CTG
GAA CTC ACC TA- 3′, reverse primer 5′ - TTG GTG
TCTATC AGT GTG AGA - 3′, product size 388 bp.
Results
Previous results of Western analysis (Figure 1a and
Additional file 1: Table S1) of primary breast cancer
extracts from the OHSU Knight Cancer Institute Breast
Cancer Tumor Repository for the presence of GRB7 and
HER-2 proteins reported that GRB7 over-expression was
found in the absence of HER-2 over-expression in 30 of
564 or 5% of tumors (Ramsey et al. 2011). When tumors
with this discordant GRB7/HER-2 protein expression
pattern were analyzed for HER-2 gene amplification
with an FDA approved, commercially available FISH
assay (PathVysion, Abbott Labs), 6 of 27 samples scored
amplified for HER-2 (Table 1). Additionally, one frozen
tumor specimen among 50 obtained from National
Disease Research Interchange (NDRI) was also found to
have isolated GRB7 protein over-expression and scored
HER-2 FISH amplified.
IHC analysis of the seven discordant tumors with a
HER-2 immunohistochemistry (IHC) assay revealed scores
of either 0 or 1+ for HER-2 protein expression. Some of
these tumors exhibited a granular cytoplasmic pattern of
HER-2 staining but the intensity and pattern were
distinctly different from the 3+ strongly positive membrane
staining pattern (Figure 1b) (Taylor et al. 1998).
In order to examine the transcript levels of HER-2 and
GRB7, we developed a multi-plex RT-PCR assay with
β-actin as an internal control (Figure 1c). Among the
7 tumors, 4 showed elevated GRB7 mRNA expression
but no elevated HER-2 mRNA expression. Two tumors
demonstrated neither GRB7 nor HER-2 mRNA over-
expression, while results for the seventh tumor indicated
both HER-2 and GRB7 mRNA over-expression (Table 2).
Sequencing of the coding region of HER-2 for the seventhTable 1 GRB7 and HER2 protein over-expression and
HER2 gene amplification by FISH analysis
Western
result






high high 66 32 32 100
high low 30 27 6 22
low high 66 35 1 3
low low 402 4 0 0tumor was conducted and revealed no apparent deleterious
sequence changes in the coding region.
Multi-probe FISH analysis, designed to examine the
extent of HER-2 gene amplification in samples with
apparent HER-2 gene amplification but no concurrent
HER-2 protein over-expression, used two flanking probes
that define the centromeric and telemetric ends of the
smallest amplified segment of the HER-2 region;
BAC probe 3014 and 3079 respectively (Figure 2a)
(Staaf et al. 2010). One sample out of 7 demonstrated de-
creased levels of gene amplification with these flanking
probes; a ratio drop from 2.5 to below 2.0, indicating a
lack of complete amplification of the smallest amplified
region from HER-2 in this sample (Sample ID 131)
(Figure 2b).
To confirm our observation that at least in some
breast cancers apparent HER-2 gene amplification
without HER-2 over-expression is due to incomplete,
or unproductive, amplification of the smallest amplified
HER-2 region, we examined an independent set of primary
breast tumor data from The Cancer Genome Atlas Project
(TCGA) and a panel of established breast cancer cell lines
from SU2C (Stand up to Cancer) (Heiser et al. 2012). The
HCC 3153 cell line, which does not over-express
HER-2 or GRB7 RNA, scored amplified by currently
available HER-2 FISH testing with a ratio of 2.65
(Figure 3a). Array hybridization revealed that cell line
HCC3153 has both HER-2 and GRB7 genes amplified
but that the extent of the amplification does not
extend to cover the smallest amplified region in its entirety
(accession no. EGAS00000000059 in the European
Genome-Phenome Archive (EGA); and accession no.
E-MTAB-181 in the ArrayExpress) (44). Western analysis
confirmed the lack of HER-2 protein over-expression
(Figure 3b). HCC3153, therefore, is a cell line model of
HER-2 gene amplification without HER-2 over-expression.
A survey of gene copy number for 847 primary breast
tumors available in the TCGA database found 10 tumors
which had gene copy number increases in only part of the
140 kb genomic segment centering around HER-2. These
samples have a log2 ratio of 0.5 or higher, a value
commonly used as the cut-off for amplification in
array analysis, for part of this region from the GISTIC2
database. Five samples out of ten had ratios greater than
1.0, a cut off for high level of 17q11-12 amplification.
None of the samples demonstrated HER-2 mRNA
over-expression based on RNAseq analysis in TCGA. Data
regarding HER-2 protein expression determined by IHC,
available for all but one tumor, showed that all specimens
scored less than 3+ for HER-2 staining (Table 3).
Discussion
Working with a well-annotated frozen breast tumor
repository, our laboratory has been studying tumors with
Table 2 Summary of protein, mRNA and FISH results for HER-2 FISH positive tumors that do not over-express HER-2
protein and comparison group of HER-2 FISH positive tumors that do over-express HER-2 protein
ID number Western Western IHC FISH FISH FISH RT-PCR RT-PCR
GRB7 HER2 HER2 HER2 BAC 3079 BAC 3014 GRB7 HER2
016 high low 1 + 2.58 NA NA low low
031 high low Cyto Gran Stain > 3.04 2.80 2.73 high low
131 high low 1 + 2.52 1.98 1.94 high low
412 high low 1 + 2.78 2.86 2.86 high low
457 high low Cyto Gran Stain 5.21 5.27 5.32 high low
517 high low Cyto Gran Stain > 3.39 2.78 2.89 low low
213 high low Cyto Gran Stain 4.44 2.48 3.59 high high
012 high high 3 + > 5.13 NA NA high high
020 high high 3 + 5.28 NA NA NA NA
276 high high 3 + 4.90 NA NA NA NA
327 high high 3 + 4.48 3.77 3.77 high high
334 high high 3 + 4.93 NA NA high high
369 high high 3 + 4.98 4.06 4.02 high high
433 high high NA 4.37 4.81 4.54 high high
772 high high NA 4.59 5.18 5.18 high high
FISH scores represent the ratio of signals derived from HER-2 region specific probes over that derived from the chromosome 17 centromeric region probe
(D17Z1). NA = not analyzed.
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part of these studies, we previously performed Western
analysis of the expression of HER-2 and GRB7 protein,
the products of two closely linked genes, which are often
over-expressed in tandem when 17q11-12 amplification
is present. Analysis of these data finds discordance in
HER-2 and GRB7 protein over-expression and shows
GRB7 protein over-expression to be a stronger independent
predictor of adverse prognosis than the over-expression of
the HER-2 protein. Additionally, we found that the breast
cancer patient population with isolated GRB7 protein
over-expression appears to have the worst prognosis
(Ramsey et al. 2011). Studies by others likewise report
that GRB7 protein over-expression is an adverse prognostic
factor in triple negative breast cancer (Nadler et al. 2010;
Sparano et al. 2011).
In order to elucidate possible mechanisms involving
GRB7 protein over-expression without HER-2 over-
expression, we performed a standard clinical FISH
analysis for HER-2 gene amplification. Surprisingly, 6 of
27 tumors scored positive for HER-2 gene amplification
with this assay. This result was unexpected since these
samples did not over-express HER-2 protein by Western
analysis. Though these patients were diagnosed as
HER-2 positive by FISH analysis, the gold standard
for HER-2 clinical laboratory testing, such patients
seem unlikely to benefit from HER-2 targeted therapy
given the absence of HER-2 protein.
Because the accurate determination of HER-2 status is
essential to treatment, we subjected our set of tumors toa standard clinical assay for HER-2 protein by IHC and
found those results to be consistent with the lack of
HER-2 protein over-expression found with Western
analysis. However, using a Multi-plex RT-PCR assay, we
found mixed results for HER-2 and GRB7 mRNA expres-
sion. Four out of 7 specimens over-expressed GRB7 but
not HER-2 mRNA. This result seems consistent with
over-expression of the GRB7 protein rather than
HER-2 in some tumors. This suggests that GRB7 can
be the focus for gene amplification and selective retention
of the 17q11-12 segment and lends further evidence to the
role of GRB7 protein over-expression as an independent
adverse prognostic factor in breast cancer.
Two of 7 samples failed to over-express GRB7 or HER-2
mRNA despite isolated GRB7 protein over-expression.
One of the 7 samples (sample ID 213) over-expressed both
HER-2 and GRB7 mRNA but sequencing of the coding
region of HER-2 mRNA for this tumor found no mutation
in its open reading frame, suggesting post-transcriptional
regulation of HER-2 expression. The mRNA and protein
expression pattern in this tumor is nonetheless consistent
with the concept of GRB7 gene being the focus of
17q11-12 amplification and selective retention.
Cases of HER-2 FISH positive but IHC negative
tumors have been reported in the past, making up about
2% of all breast cancer patients or 10% of HER-2 FISH
positive breast tumors (Sauter et al. 2009; Lipton et al.
2010). Much of this discrepancy has been attributed to
pre-analytic and analytic issues associated with IHC
of paraffin preserved sections. Our finding of frozen
Figure 2 A multiple-probe FISH analysis of the HER-2 and GRB7 segment from human chromosome 17q11-12. a A 140 kb genomic
segment centered on HER-2 from human chromosome 17q11-12. a A 140 kb genomic segment centered on HER-2 from human chromosome
17q11-12. A. The stippled box represents the smallest amplified region from HER-2 previously identified. B. Five genes from this region shown are
STARD3, PGAP3, HER-2, GRB7 and IKZF3. C. The mapping positions of two BACs (#3014 and #3079) that define the centromeric and telomeric
ends of the smallest amplified region are shown. D. Filled box represents the extent of gene amplification from the HER-2 region for the cell line
HCC-3153. b FISH analysis of human breast tumor cells from tumor #031. HER-2 FISH was performed using the Abbott PathVysion kit on 4 μm
frozen sections. Probe for the HER-2 locus (17q12, SpectrumOrange) and the chromosome 17 centromere (CEP17) as the chromosome 17 control
probe (D17Z1,17p11.1-q11.1, SpectrumGreen). BAC 3079, BAC 3014. Purified 5′probe #3014 was labeled with Abbott SpectrumGreen (green
fluorescence). Purified 3′probe #3079 was labeled with Abbott SpectrumOrange (orange fluorescence), and the commercially available
chromosome 17 centromere probe with Abbott SpectrumAqua (aqua fluorescence). Coalescence of orange and green fluorescence signals yield
yellow signals indicating that sequences represented by both probes are amplified in one contiguous unit.
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gene amplification by FISH but do not over-express
HER-2 protein by Western analysis nor HER-2 mRNA by
RT-PCR, indicates some of these tumors may indeed be
true HER-2 FISH false positives- i.e. HER-2 gene amplifica-
tion without concomitant protein over-expression. Of note,
we did not perform HER-2 FISH analysis of all 563 patient
samples in our cohort, but based on the distribution and
incidence of HER-2 FISH amplified cases in subsets
of this tumor cohort we estimate 10% of tumors that
were FISH amplified would not over-express HER-2
protein on Western analysis.
In an attempt to understand the mechanism of isolated
GRB7 protein over-expression, we speculated that perhaps
only a portion of the HER-2 gene is amplified. The HER-2FISH probe utilized in the commonly employed Abbott
PathVysion Kit covers a 190 kb genomic segment of
chromosome 17q11-12 that contains both HER-2 and
GRB7 genes and may score positive when only part of the
HER-2 gene or GRB7 gene alone is amplified. Therefore
we developed a multi-probe FISH assay with a set of
flanking probes that demarcate the centromeric and
telomeric ends of the smallest amplified region, which was
previously identified as 90 kb in length (Staaf et al. 2010).
Utilizing this strategy, we were able to perform multi-
probe FISH analysis on 6 of the 7 samples. Four of the
samples (131, 517, 213 and 031) showed different and
lower copy numbers when flanking probes were used
rather than the commercial probe, which targets the central
portion of the amplified region. In the case of specimen
Figure 3 A human breast cancer cell line with HER-2 gene amplification but no concurrent HER-2 over-expression. a HER-2 gene
amplification in breast cancer cell line HCC3153 Red: HER-2 by PathVysion probe; Green: Chromosome 17centromere. b Western analysis of HER-2
protein expression of breast cancer cell lines.
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smallest amplified region in its entirety, possibly explaining
why this sample, though scoring positive for HER-2 gene
amplification by current commercial assay, fails to
over-express HER-2 protein or HER-2 mRNA. Current
HER-2 FISH testing strategy cannot accurately discern the
HER-2 amplification status of this sample.Table 3 TCGA tumors positive for partial HER-2 region
amplification but with low HER-2 mRNA expression





TCGA-D8-A1JG 0.58 1.09 2 +
TCGA-AN-A041 0.64 0.88 2 +
TCGA-A8-A070 0.72 - 5.50 1 +
TCGA-A8-A0AD 0.74 - 0.65 1 +
TCGA-D8-2A7G 0.78 - 2 +
TCGA-A2-A0YE 1.12 - 4.00 0 +
TCGA-C8-A26X 1.14 - 2.74 1 +
TCGA-A7-A13D 1.68 - 2.57 2 +
TCGA-A8-A06U 1.81 - 1.70 2 +
TCGA-BH-A1EN 6.00 - 3.90 -We turned to the SU2C and TCGA databases to
search for a similar pattern of HER-2 protein expression
and gene amplification in breast cancer cell lines and
other patient cohorts. We found that the breast cancer
cell line HCC 3153 displays an amplification in only part
of the smallest amplified region from the 17q11-12
region based on array analysis, though scoring positive
with the standard HER-2 FISH assay. This cell line
fails to over-express either HER-2 or GRB7 mRNA or
protein. Thus we have identified a cell line model of
HER-2 gene amplification without protein or mRNA over-
expression that independently confirms our observation
using banked frozen tumors.
A survey of the TCGA database (N = 847) found 10
tumors with only partial amplification of the HER-2
region based on array hybridization, though these tumors
would be expected to score amplified with currently avail-
able HER-2 FISH assays. None of these tumors exhibited
HER-2 mRNA or protein over-expression. This result indi-
cates in this cohort derived from the TCGA database that
about 5% of HER-2 amplification events occur without
concurrent HER-2 over-expression and that this is
due to partial amplification of the HER-2 region. This
observation helps confirm our view that incomplete
Luoh et al. SpringerPlus 2013, 2:386 Page 9 of 10
http://www.springerplus.com/content/2/1/386or partial amplification of the smallest amplified region of
HER-2 may be problematic for current FISH and CISH
assay methods that use only a single HER-2 probe.
In conclusion, our work provides evidence that the GRB7
gene may be the focus of some cases of the chromosome
17q11-12 amplification and selective retention, further
strengthening the prognostic importance of GRB7 protein
over-expression in breast cancer. In addition, we have
established that a subset (approximately 5-10%) of primary
breast cancers, considered as HER-2 amplified by the
current FISH assay, are actually HER-2 false positive due to
incomplete amplification of the smallest HER-2 region.
Given this circumstance, multi-probe FISH may represent a
potential strategy to avoid this pitfall and improve HER-2
FISH testing accuracy. Accurate determination of
HER-2 status is essential since patients whose tumors
have HER-2 gene amplification but no protein over-
expression are unlikely to benefit from current HER-2
targeted therapies.
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